Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Pfizer CEO Albert Bourla stated that uncertainty over Trump’s planned pharmaceutical tariffs is deterring new U.S.

U.S. pharmaceutical imports surged in March, exceeding $50 billion, as drugmakers stockpiled inventory in anticipation of ...

Pfizer CEO Albert Bourla said Tuesday that uncertainty surrounding President Donald Trump’s proposed pharmaceutical tariffs is discouraging the company from making additional investments in U.S.

President Donald Trump on Monday signed an executive order to incentivize drug manufacturing in the U.S., streamlining the ...

Pfizer has promoted Albert Bourla, seen as a likely successor to incumbent CEO Ian Read, to the newly-created role of chief operating officer. The move could help Read focus on long-term strategy ...

The $40 billion investment will be spread across various R&D and manufacturing areas over the next five years.

Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet ...